Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9374563 | 0.93 | SIGMAR1 (0.46) | SIGMAR1HRH3CARM1PRMT6PRMT1 | |
| SCHEMBL15363082 | 0.92 | GNAO1 (0.56) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL8345209 | 0.92 | GNAO1 (0.56) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL1071607 | 0.92 | GNAO1 (0.56) | SIGMAR1GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL23004447 | 0.90 | GNAO1 (0.59) | SIGMAR1GNAI3GNAO1GNAI1 | |
| Iodide SCHEMBL23004297 | 0.90 | GNAO1 (0.55) | SIGMAR1GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL23004142 | 0.90 | GNAO1 (0.59) | SIGMAR1GNAI3GNAO1GNAI1 | |
| Iodide SCHEMBL23004334 | 0.90 | GNAO1 (0.55) | SIGMAR1GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL23004147 | 0.90 | GNAO1 (0.59) | SIGMAR1GNAI3GNAO1GNAI1 | |
| Iodide SCHEMBL23004475 | 0.90 | GNAO1 (0.55) | SIGMAR1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9408888-B2 | High affinity bivalent helically constrained peptide against cancer | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-08-09 | — | — | US | disclosed |
| US-20140155331-A1 | NOVEL HIGH AFFINITY BIVALENT HELICALLY CONSTRAINED PEPTIDE AGAINST CANCER | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155331-A1 | NOVEL HIGH AFFINITY BIVALENT HELICALLY CONSTRAINED PEPTIDE AGAINST CANCER | S100B, TP53, S100P | SIGMAR1 4008/4885HRH3 1554/4885GNAI3 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.